Melinta Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MELINTA, and what generic alternatives to MELINTA drugs are available?
MELINTA has four approved drugs.
There are sixteen US patents protecting MELINTA drugs.
There are one hundred and thirty-four patent family members on MELINTA drugs in twenty-eight countries and twenty-seven supplementary protection certificates in sixteen countries.
Drugs and US Patents for Melinta
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 8,648,093 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 9,200,088 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | RX | Yes | Yes | 8,252,813 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | RX | Yes | Yes | 7,728,143 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Melinta
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,840,684 | ⤷ Try a Trial |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,998,581 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Melinta Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | PI0905080 | ⤷ Try a Trial |
Poland | 3056492 | ⤷ Try a Trial |
Denmark | 2346855 | ⤷ Try a Trial |
South Korea | 101633479 | ⤷ Try a Trial |
Norway | 2016019 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Melinta Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2337575 | 41/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323 |
2337575 | 1690041-7 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323 |
3214083 | 2021C/504 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACINE OU UN SEL OU ESTER DE CELLE-CI, Y COMPRIS LA DELAFLOXACINE MEGLUMINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1393 20191219 |
3214083 | 21C1006 | France | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACINE; REGISTRATION NO/DATE: EU/1/19/1393 20191219 |
3214083 | C20210002 00366 | Estonia | ⤷ Try a Trial | PRODUCT NAME: DELAFLOKSATSIIN;REG NO/DATE: EU/1/19/1393 19.12.2019 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.